Upstream therapies for management of atrial fibrillation: Review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: Primary prevention

Europace

Volumn 13, Issue 3, 2011, Pages 308-328

  Savelieva, Irene ^a   Kakouros, Nicholaos ^a   Kourliouros, Antonios ^a   Camm, A John ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Aldosterone antagonists; Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Atrial fibrillation; Corticosteroids; HMG CoA reductase inhibitors; n 3 ( 3) Polyunsaturated fatty acids; Prevention; Remodelling; Statins

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; DOXAZOSIN; ENALAPRIL; EPLERENONE; EZETIMIBE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; IRBESARTAN; LISINOPRIL; LOSARTAN; MEVINOLIN; PRAVASTATIN; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; SPIRONOLACTONE; TELMISARTAN; TIROFIBAN; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN;

ACUTE CORONARY SYNDROME; ANTIARRHYTHMIC ACTIVITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART PACING; HUMAN; HYPERTENSION; NONHUMAN; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SECONDARY PREVENTION; STROKE; THERAPY; TRANSIENT ISCHEMIC ATTACK; UPSTREAM THERAPY;

ADRENAL CORTEX HORMONES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ATRIAL FIBRILLATION; FATTY ACIDS, OMEGA-3; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MODELS, ANIMAL; PRACTICE GUIDELINES AS TOPIC;

EID: 79952217693     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur002     Document Type: Review

References (181)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5. (Pubitemid 32424106)
2. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25. (Pubitemid 44420743)
3. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534-9.
4. Heeringa J, van der Kuip DA, Hofman A, Hofman A, Breteler MM, Lip GY et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-53.
5. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 2000;4: 369-82.
6. Camm AJ, Kirchhof P, Lip GYH, Savelieva I, Ernst S. Atrial fibrillation. In Camm AJ, Lúśher TF, Serruys PW (eds). The ESC Textbook of Cardiovascular Medicine. Oxford: Blackwell Publishing Ltd; 2009. p1069-132.
7. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD et al. Investigators of the Ischemia Research and Education Foundation; Multicenter Study of Perioperative Ischemia Research Group. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004;291:1720-9. (Pubitemid 38489894)
8. Savelieva I, Camm J. Is there any hope for angiotensin-converting enzyme inhibitors in atrial fibrillation? Am Heart J 2007;154:403-6. (Pubitemid 47268247)
9. Goette A, Lendeckel U. Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms. Europace 2008;10: 238-41. (Pubitemid 351767699)
10. Cardin S, Li D, Thorin-Trescases N, Leung TK, Thorin E, Nattel S. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovasc Res 2003;60: 315-25. (Pubitemid 37412365)
11. Goette A, Staack T, Röcken C, Arndt M, Geller JC, Huth C et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35: 1669-77. (Pubitemid 30307515)
12. Boldt A, Wetzel U, Weigl J, Garbade J, Lauschke J, Hindricks G et al. Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 2003;42: 1785-92. (Pubitemid 37433659)
13. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001;104:2608-14. (Pubitemid 33104801)
14. Liu T, Korantzopoulos P, Xu G, Shehata M, Li D, Wang Z et al. Association between angiotensin-converting enzyme insertion/deletion gene polymorphism and atrial fibrillation: a meta-analysis. Europace 2011;13:346-354.
15. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003;41:2197-204. (Pubitemid 36724267)
16. Moreno I, Caballero R, Gonzalez T, Arias C, Valenzuela C, Iriepa I et al. Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization. J Pharmacol Exp Ther 2003;304:862-73. (Pubitemid 36152367)
17. Saygili E, Rana OR, Saygili E, Reuter H, Frank K, Schwinger RH et al. Losartan prevents stretch-induced electrical remodeling in cultured atrial neonatal myocytes. Am J Physiol Heart Circ Physiol 2007;292:H2898-905. (Pubitemid 47084539)
18. Chen YJ, Chen YC, Tai CT, Yeh HI, Lin CI, Chen SA. Angiotensin II and angiotensin II receptor blocker modulate the arrhythmogenic activity of pulmonary veins. Br J Pharmacol 2006;147:12-22.
19. Shetty SS, DelGrande D. Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan. J Pharmacol Exp Ther 2000;294:179-86. (Pubitemid 30434685)
20. Dhein S. Role of connexins in atrial fibrillation. Adv Cardiol 2006;42:161-74. (Pubitemid 43805863)
21. Goette A, Bukowska A, Lendeckel U, Erxleben M, Hammwöhner M, Strugala D et al. Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation 2008;117:732-42. (Pubitemid 351640674)
22. Yamagishi S, Takenaka K, Inoue H. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation. Med Hypotheses 2006;66:118-20. (Pubitemid 41605116)
23. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA 1994;271:840-4.
24. Tsang TS, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 2002;40: 1636-44. (Pubitemid 35253642)
25. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RB Sr et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009;373:739-45.
26. De Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010;55:725-31.
27. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920-5. (Pubitemid 36736633)
28. Pedersen OD, Bagger H, K'ber L, Torp-Pedersen C. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. Eur Heart J 1999;20: 748-54. (Pubitemid 29209908)
29. Pedersen OD, Bagger H, Keller N, Marchant B, K'ber L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) substudy. Circulation 2001;104: 292-6. (Pubitemid 32666950)
30. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358:2667-77. (Pubitemid 351860859)
31. Shelton RJ, Clark AL, Goode K, Rigby AS, Houghton T, Kaye GC et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart 2009;95: 924-30.
32. Guglin M, Chen R, Curtis AB. Sinus rhythm is associated with fewer heart failure symptoms: insights from the AFFIRM trial. Heart Rhythm 2010;7:596-601.
33. Savelieva I, Camm AJ. Atrial fibrillation and heart failure: natural history and pharmacological treatment. Europace 2004;5:S5-19. (Pubitemid 39193160)
34. Shinagawa K, Shi YF, Tardif JC, Leung TK, Nattel S. Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs. Circulation 2002;105:2672-8. (Pubitemid 34596046)
35. Cha TJ, Ehrlich JR, Zhang L, Shi YF, Tardif JC, Leung TK et al. Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure. Circulation 2004;109:412-8. (Pubitemid 38133912)
36. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation 1994; 89:724-30. (Pubitemid 24056200)
37. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376-80. (Pubitemid 29362407)
38. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003;107:2926-31. (Pubitemid 36736634)
39. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005;149:548-57. (Pubitemid 40585420)
40. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152:86-92.
41. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456-67.
42. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-9. (Pubitemid 40789940)
43. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin- angiotensin system prevents new-onset atrial fibrillation. Am Heart J 2006;152: 217-22. (Pubitemid 44093401)
44. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis. Am J Ther 2008;15:36-43. (Pubitemid 351161180)
45. Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010;55:2299-307.
46. Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:705-11. (Pubitemid 40282585)
47. Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol 2009;54:2023-31.
48. Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens 2008;21:500-8. (Pubitemid 351589672)
49. Wachtell K, Gerdts E, Aurigemma GP, Boman K, Dahlö f B, Nieminen MS et al. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the LIFE study. Blood Press 2010;19:169-75.
50. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999;353:611-6. (Pubitemid 29087980)
51. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.
52. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-9. (Pubitemid 40282586)
53. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006;296:1242-8. (Pubitemid 44394895)
54. L'Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC Angiotensin converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004;44: 159-16.
55. Shaer BA, Schneider C, Jick SS, Conen D, Osswald S, Meier CR. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case- control study. Ann Intern Med 2010;152:78-84.
56. Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008;26:403-11. (Pubitemid 351317247)
57. Salehian O, Healey J, Stambler B, Alnemer K, Almerri K, Grover J et al. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Am Heart J 2007;154:448-53. (Pubitemid 47271928)
58. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008;372:1174-83.
59. Mitchell LB, Crystal E, Heilbron B, Pagé P. Atrial fibrillation following cardiac surgery. Can J Cardiol 2005;21:45B-50B. (Pubitemid 46639166)
60. Ahlsson A, Fengsrud E, Bodin L, Englund A. Postoperative atrial fibrillation in patients undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial fibrillation and a doubled cardiovascular mortality. Eur J Cardiothorac Surg 2010;37:1353-9.
61. White CM, Kluger J, Lertsburapa K, Faheem O, Coleman CI. Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the Atrial FIbrillation Suppression Trials II and III. Eur J Cardiothorac Surg 2007;31:817-20.
62. Shariff N, Zelenkofske S, Eid S, Weiss MJ, Mohammed MQ. Demographic determinants and effect of pre-operative angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the occurrence of atrial fibrillation after CABG surgery. BMC Cardiovasc Disord 2010;10:7.
63. Coleman CI, Makanji S, Kluger J, White CM. Effect of angiotensin- converting enzyme inhibitors or angiotensin receptor blockers on the frequency of postcardiothoracic surgery atrial fibrillation. Ann Pharmacother 2007;41:433-7. (Pubitemid 46536034)
64. Ozaydin M, Dede O, Varol E, Kapan S, Turker Y, Peker O et al. Effect of renin- angiotensin aldosteron system blockers on postoperative atrial fibrillation. Int J Cardiol 2008;127:362-7. (Pubitemid 351885086)
65. Defaye P, Dournaux F, Mouton E. Prevalence of supraventricular arrhythmias from the automated analysis of data stored in the DDD pacemakers of 617 patients: the AIDA study. The AIDA Multicenter Study Group. Automatic Interpretation for Diagnosis Assistance. Pacing Clin Electrophysiol 1998;21:250-5.
66. Toff WD, Camm AJ, Skehan JD, United Kingdom Pacing and Cardiovascular Events Trial Investigators. Single-chamber versus dual-chamber pacing for highgrade atrioventricular block. N Engl J Med 2005;353:145-55. (Pubitemid 41058346)
67. Skanes AC, Krahn AD, Yee R, Klein GJ, Connolly SJ, Kerr CR et al. Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing. CTOPP Investigators. J Am Coll Cardiol 2001;38:167-72. (Pubitemid 32613845)
68. Williams SG, Connelly DT, Jackson M, Bennett A, Albouaini K, Todd DM. Does treatment with ACE inhibitors or angiotensin II receptor antagonists prevent atrial fibrillation after dual chamber pacemaker implantation? Europace 2005;7: 554-9. (Pubitemid 41488099)
69. Urata H. Pathological involvement of chymase-dependent angiotensin II formation in the development of cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2000;1:35-7.
70. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101:2612-7. (Pubitemid 30350640)
71. Yin Y, Dalal D, Liu Z, Wu J, Liu D, Lan X et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006;27:1841-6. (Pubitemid 44297391)
72. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59. (Pubitemid 351522739)
73. Fogari R, Derosa G, Ferrari I, Corradi L, Zoppi A, Lazzari P et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J Hypertens 2008;21:1034-9.
74. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12:1360-420.
75. Savelieva I, Kakouros N, Kourliouros A, Camm J. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for ESC guidelines. Part II: secondary prevention. Europace 2011 (in press).
76. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243-8. (Pubitemid 40523144)
77. Tsai CT, Chiang FT, Tseng CD, Hwang JJ, Kuo KT, Wu CK et al. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol 2010;55:758-70.
78. Yang SS, Han W, Zhou HY, Dong G, Wang BC, Huo H et al. Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. Chin Med J (Engl) 2008;121:38-42.
79. Laszlo R, Bentz K, Konior A, Eick C, Schreiner B, Kettering K et al. Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits. Naunyn Schmiedebergs Arch Pharmacol 2010;382:347-56.
80. Brinkley DM, Chen J. Effect of spironolactone on atrial fibrillation in patients with heart failure. Heart Rhythm 2010;7:S262 (Abstract).
81. Kourliouros A, Savelieva I, Kiotsekoglou A, Jahangiri M, Camm J. Current concepts in the pathogenesis of atrial fibrillation. Am Heart J 2009;157:243-52.
82. Shiroshita-Takeshita A, Brundel BJ, Lavoie J, Nattel S. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc Res 2006;69:865-875. (Pubitemid 43227985)
83. Marik PE, Fromm R. The efficacy and dosage effect of corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a systematic review. J Crit Care 2009;24:458-463.
84. Ishii Y, Schuessler RB, Gaynor SL, Yamada K, Fu AS, Boineau JP et al. Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation. Circulation 2005;111:2881-8. (Pubitemid 40814180)
85. Ryu K, Li L, Khrestian CM, Matsumoto N, Sahadevan J, Ruehr ML et al. Effects of sterile pericarditis on connexins 40 and 43 in the atria-correlation with abnormal conduction and atrial arrhythmias. Am J Physiol Heart Circ Physiol 2007;293: H1231-41. (Pubitemid 47254226)
86. Anné W, Willems R, Roskams T, Sergeant P, Herijgers P, Holemans P et al. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation. Cardiovasc Res 2005;67:655-66. (Pubitemid 41033361)
87. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96:1180-4. (Pubitemid 27344221)
88. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006-10. (Pubitemid 37553570)
89. Zacks ES, Okin PM, Min J, Roman MJ, Lee ET, Howard BV et al. Association of markers of inflammation with new onset atrial fibrillation in a population-based sample: the Strong Heart Study. Circulation 2006;114:II-678 (Abstract).
90. Marcus GM, Whooley MA, Glidden DV, Pawlikowska L, Zaroff JG, Olgin JE. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am Heart J 2008;155:303-9.
91. Liu T, Li L, Korantzopoulos P, Goudevenos JA, Li G. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 2007;49:1642-8. (Pubitemid 46551628)
92. Watanabe H,Watanabe T, Sasaki S, AizawaY. Dyslipidemia and risk of atrial fibrillation: the Niigata Preventive Medicine Study. Circulation 2009: Abstract 1458.
93. Chamberlain AM, Agarwal SK, Ambrose M, Folsom AR, Soliman EZ, Alonso A. Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2010;159: 850-6.
94. Savelieva I, Kourliouros A, Camm J. Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. Naunyn Schmiedebergs Arch Pharmacol 2010;381:1-13.
95. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004;62:105-11. (Pubitemid 38326816)
96. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. The effect of simvastatin and antioxidant vitamins on atrial fibrillation-promotion by atrial tachycardia remodeling in dogs. Circulation 2004;110:2313-9. (Pubitemid 39407332)
97. Shiroshita-Takeshita A, Brundel BJ, Burstein B, Leung TK, Mitamura H, Ogawa S et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res 2007;74:75-84. (Pubitemid 46366949)
98. Hanna IR, Heeke B, Bush H, Brosius L, King-Hageman D, Dudley SC Jr et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006;3: 881-6. (Pubitemid 44103516)
99. Dickinson MG, Hellkamp AS, Ip JH, Anderson J, Johnson GW, Singh SN et al. Statin therapy was associated with reduced atrial fibrillation and flutter in heart failure patients in SCD-HEFT. Heart Rhythm 2006;3:S49 (Abstract).
100. Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG, Latini R et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J 2009;19:2327-36.
101. Kotlewski A, Liu ILA, Khan SS, Shen AY, Brar SS. Prevalence of atrial fibrillation and flutter by different HMG-CoA reductase inhibitors and doses in heart failure. J Am Coll Cardiol 2006;47:61A (Abstract).
102. Izzo R, de Simone G, Trimarco V, Chinali M, Giudice R, Vasta A et al. Abstract 2997: statins therapy and atrial fibrillation in hypertensive patients. Circulation 2008;118:II-802 (Abstract).
103. Macfarlane PW, Murray H, Sattar N, Stott D, Ford I, Buckley B et al.. The incidence and risk factors for new onset atrial fibrillation in the PROSPER study. Europace 2011[Epub ahead of press]
104. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992;326: 242-50.
105. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003;92:1379-83. (Pubitemid 37532555)
106. Pellegrini CN, Vittinghoff E, Lin F, Hulley SB, Marcus GM. Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial. Heart 2009;95:704-8.
107. Bang CA, Greve M, Olsen HM, Kober L, Wachtell K. Effect of statin treatment on atrial fibrillation in patients with asymptomatic aortic stenosis: a SEAS substudy. Eur Heart J 2010;31:Abstract 715.
108. Adabag AS, Nelson DB, Bloomfield HE. Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure. Am Heart J 2007;154: 1140-5. (Pubitemid 350116030)
109. Adabag AS, Mithani S, Al Aloul B, Collins D, Bertog S, Bloomfield HE et al. Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial. Am Heart J 2009;157:913-8.
110. Vedre A, Gurm HS, Froehlich JB, Kline-Rogers E, Montalescot G, Gore JM et al. Impact of prior statin therapy on arrhythmic events in patients with acute coronary syndromes (from the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol 2009;104:1613-7.
111. Ramani G, Zahid M, Good CB, Macioce A, Sonel AF. Comparison of frequency of new-onset atrial fibrillation or flutter in patients on statins versus not on statins presenting with suspected acute coronary syndrome. Am J Cardiol 2007;100: 404-5. (Pubitemid 47094684)
112. Danchin N, Fauchier L, Marijon E, Barnay C, Furber A, Mabo P et al. or the French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) Investigators. Impact of early statin therapy on development of atrial fibrillation at the acute stage of myocardial infarction: data from the FAST-MI register. Heart 2010;96:1809-814.
113. Kulik A, Singh JP, Levin R, Avorn J, Choudhry NK. Association between statin use and the incidence of atrial fibrillation following hospitalization for coronary artery disease. Am J Cardiol 2010;105:1655-60.
114. Schwartz GG, Olsson AG, Chaitman B, Goldberg J, Szarek M, Sasiela WJ. Effect of intensive statin treatment on the occurrence of atrial fibrillation after acute coronary syndrome: an analysis of the MIRACL trial. Circulation 2004;110: III-740 (Abstract).
115. McLean DS, Ravid S, Blazing M, Gersh B, Shui A, Cannon CP. Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials. Am Heart J 2008;155: 298-302.
116. Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008;51:828-35. (Pubitemid 351255618)
117. Schwartz GG, Chaitman BR, Goldberger JJ, Messig M, on behalf of the Steering Committee of the SPARCL trial. Effect of high-dose atorvastatin on risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Circulation 2010: Abstract 10897.
118. Dotani MI, Elnicki DM, Jain AC, Gibson CM. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 2000;86: 1128-30.
119. Marin F, Pascual DA, Roldan V, Arribas JM, Ahumada M, Tornel PL et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 2006;97:55-60. (Pubitemid 41828123)
120. Lertsburapa K, White CM, Kluger J, Faheem O, Hammond J, Coleman CI. Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery. J Thorac Cardiovasc Surg 2008;135:405-11. (Pubitemid 351192943)
121. Kourliouros A, De Souza A, Roberts N, Marciniak A, Tsiouris A, Valencia O et al. Dose-related effect of statins on atrial fibrillation after cardiac surgery. Ann Thorac Surg 2008;85:1515-20. (Pubitemid 351618357)
122. Mithani S, Akbar MS, Johnson DJ, Kuskowski M, Apple KK, Bonawitz-Conlin J et al. Dose dependent effect of statins on postoperative atrial fibrillation after cardiac surgery among patients treated with beta blockers. J Cardiothorac Surg 2009;4:61.
123. Kourliouros A, Valencia O, Tavakkoli Hosseini M, Mayr M, Sarsam M, Camm J et al. Preoperative high-dose atorvastatin for prevention of atrial fibrillation after cardiac surgery. J Thorac Cardiovasc Surg 2011;141:244-8.
124. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E et al.
125. Song YB, On YK, Kim JH, Shin DH, Kim JS, Sung J et al. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am Heart J 2008;156:373 e9-16.
126. Liakopoulos OJ, Choi YH, Kuhn EW, Wittwer T, Borys M, Madershahian N et al. Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review. J Thorac Cardiovasc Surg 2009;138:678-86.
127. Chen WT, Krishnan GM, Sood N, Kluger J, Coleman CI. Effects of statins on atrial fibrillation after cardiac surgery: a duration- and dose-response meta-analysis. J Thorac Cardiovasc Surg 2010;140:364-72.
128. Subramaniam K, Koch CG, Bashour A, O'Connor M, Xu M, Gillinov AM et al. Preoperative statin intake and morbid events after isolated coronary artery bypass grafting. J Clin Anesth 2008;20:4-11. (Pubitemid 351381408)
129. Virani SS, Nambi V, Razavi M, Lee VV, Elayda M, Wilson JM et al. Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery. Am Heart J 2008;155: 541-46.
130. Miceli A, Fino C, Fiorani B, Yeatman M, Narayan P, Angelini GD et al. Effects of preoperative statin treatment on the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting. Ann Thorac Surg 2009;87: 1853-8.
131. Tsai CT, Lai LP, Hwang JJ, Wang YC, Chiang FT, Lin JL. Atorvastatin prevents atrial fibrillation in patients with bradyarrhythmias and implantation of an atrialbased or dual-chamber pacemaker: a prospective randomized trial. Am Heart J 2008;156:65-70.
132. Amit G, Katz A, Bar-On S, Gilutz H, Wagshal A, Ilia R et al. Association of statin therapy and the risk of atrial fibrillation in patients with a permanent pacemaker. Clin Cardiol 2006;29:249-52. (Pubitemid 43865703)
133. Gillis AM, Morck M, Exner DV, Soo A, Rose MS, Sheldon RS et al. Beneficial effects of statin therapy for prevention of atrial fibrillation following DDDR pacemaker implantation. Eur Heart J 2008;29:1873-80.
134. Santangeli P, Ferrante G, Pelargonio G, Dello Russo A, Casella M, Bartoletti S et al. Usefulness of statins in preventing atrial fibrillation in patients with permanent pacemaker: a systematic review. Europace 2010;12:649-54.
135. Liu T, Li G, Korantzopoulos P, Goudevenos JA. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol 2008;126:160-70. (Pubitemid 351602110)
136. Rahimi K, Emberson J, Mcgale P, Majoni W, Merhi A, Asselberg F et al. Effect of statins on atrial fibrillation: a collaborative meta-analysis of randomised controlled trials. Eur Heart J 2009:Abstract 2782.
137. Savelieva I, Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med 2008;5:30-41.
138. Ninio DM, Murphy KJ, Howe PR, Saint DA. Dietary fish oil protects against stretch-induced vulnerability to atrial fibrillation in a rabbit model. J Cardiovasc Electrophysiol 2005;16:1189-94.
139. Li GR, Sun HY, Zhang XH, Cheng LC, Chiu SW, Tse HF et al. Omega-3 polyunsaturated fatty acids inhibit transient outward and ultra-rapid delayed rectifier K+ currents and Na+ current in human atrial myocytes. Cardiovasc Res 2009;81: 286-93.
140. Boland LM, Drzewiecki MM. Polyunsaturated fatty acid modulation of voltagegated ion channels. Cell Biochem Biophys 2008;52:59-84.
141. 2+ exchange currents in HEK293t cells. Biochem Biophys Res Commun 2004;321:116-23. (Pubitemid 39060658)
142. Da Cunha DN, Hamlin RL, Billman GE, Carnes CA. n-3 (omega-3) polyunsaturated fatty acids prevent acute atrial electrophysiological remodeling. Br J Pharmacol 2007;150:281-5. (Pubitemid 46221037)
143. Laurent G, Moe G, Hu X, Holub B, Leong-Poi H, Trogadis J et al. Long chain n-3 polyunsaturated fatty acids reduce atrial vulnerability in a novel canine pacing model. Cardiovasc Res 2008;77:89-97. (Pubitemid 351195152)
144. Sakabe M, Shiroshita-Takeshita A, Maguy A, Dumesnil C, Nigam A, Leung TK et al. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation 2007;116: 2101-9. (Pubitemid 350060347)
145. Sarrazin JF, Comeau G, Daleau P, Kingma J, Plante I, Fournier D et al. Reduced incidence of vagally induced atrial fibrillation and expression levels of connexins by n-3 polyunsaturated fatty acids in dogs. J Am Coll Cardiol 2007; 50:1505-12. (Pubitemid 47494587)
146. Mayyas F, Sakurai S, Ram R, Rennison J, Hwang ES, Castel L et al. Dietary omega-3 fatty acids modulate the substrate for post-operative atrial fibrillation in a canine cardiac surgery model. Cardiovasc Res 2010 [Epub ahead of press].
147. Ramadeen A, Laurent G, dos Santos CC, Hu X, Connelly KA, Holub BJ et al. n-3 Polyunsaturated fatty acids alter expression of fibrotic and hypertrophic genes in a dog model of atrial cardiomyopathy. Heart Rhythm 2010;7:520-8.
148. Zhang Z, Zhang C, Wang H, Zhao J, Liu L, Lee J et al. n-3 polyunsaturated fatty acids prevent atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Int J Cardiol 2010 [Epub ahead of press].
149. Mozaffarian D, Psaty BM, Rimm EB, Lemaitre RN, Burke GL, Lyles MF et al. Fish intake and risk of incident atrial fibrillation. Circulation 2004;110:368-73. (Pubitemid 38993844)
150. Frost L, Vestergaard P. n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr 2005; 81:50-4. (Pubitemid 43073375)
151. Brouwer IA, Heeringa J, Geleijnse JM, Zock PL, Witteman JC. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am Heart J 2006;151:857-62.
152. Aizer A, Gaziano JM, Manson JE, Buring JE, Albert CM. Relationship between fish consumption and the development of atrial fibrillation in men. Heart Rhythm 2006;3:S5 (Abstract).
153. Berry JD, Prineas RJ, van Horn L, Passman R, Larson J, Goldberger J et al. Dietary fish intake and incident atrial fibrillation (from the Women's Health Initiative). Am J Cardiol 2010;105:844-8.
154. Virtanen JK, Mursu J, Voutilainen S, Tuomainen TP. Serum long-chain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. Circulation 2009;120:2315-21.
155. London B, Albert C, Anderson ME, Giles WR, Van Wagoner DR, Balk E et al. Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office Of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop. Circulation 2007;116: e320-35. (Pubitemid 47360222)
156. Macchia A, Monte S, Pellegrini F, Romero M, Ferrante D, Doval H et al. Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction. Eur J Clin Pharmacol 2008;64: 627-34.
157. Calò L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005;45:1723-8. (Pubitemid 40704512)
158. Heidt MC, Vician M, Stracke SK, Stadlbauer T, Grebe MT, Boening A et al. Beneficial effects of intravenously administered N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study. Thorac Cardiovasc Surg 2009;57:276-80.
159. Saravanan P, Bridgewater B, West AL, O'Neill SC, Calder PC, Davidson NC. Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, double-blind, placebocontrolled clinical trial. Circ Arrhythm Electrophysiol 2010;3:46-53.
160. Heidarsdottir R, Arnar DO, Skuladottir GV, Torfason B, Edvardsson V, Gottskalksson G et al. Does treatment with n-3 polyunsaturated fatty acids prevent atrial fibrillation after open heart surgery? Europace 2010;12:356-63.
161. Sandesara C, Chung MK, Van Wagoner DR et al. Fish oil to inhibit supraventricular arrhythmias after cardiac surgery: the FISH trial. HRS 2010 Oral Presentation, Friday, 18 May 2010.
162. Cereceda M, Rodrigo R, Castillo R, Pizarro R, Asenjo R, Zamorano J et al. Prevention of postoperative atrial fibrillation with the supplementation of omega-3 PUFA plus antioxidant vitamins in patients undergoing cardiac surgery with extracorporeal circulation. Circulation 2009:Abstract 2519.
163. Shiroshita-Takeshita A, Brundel BJ, Lavoie J, Nattel S. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc Res 2006;69:865-75. (Pubitemid 43227985)
164. Goldstein RN, Ryu K, Khrestian C, van Wagoner DR, Waldo AL. Prednisone prevents inducible atrial flutter in the canine sterile pericarditis model. J Cardiovasc Electrophysiol 2008;19:74-81.
165. Halvorsen P, Raeder J, White PF, Almdahl SM, Nordstrand K, Saatvedt K et al. The effect of dexamethasone on side effects after coronary revascularization procedures. Anesth Analg 2003;96:1578-83. (Pubitemid 36623109)
166. Prasongsukarn K, Abel JG, Jamieson WR, Cheung A, Russell JA, Walley KR et al. The effects of steroids on the occurrence of postoperative atrial fibrillation after coronary artery bypass grafting surgery: a prospective randomized trial. J Thorac Cardiovasc Surg 2005;130:93-8. (Pubitemid 40941674)
167. Yared JP, Bakri MH, Erzurum SC, Moravec CS, Laskowski DM, VanWagoner DR et al. Effect of dexamethasone on atrial fibrillation after cardiac surgery: prospective, randomized, double-blind, placebo-controlled trial. J Cardiothorac Vasc Anesth 2007;21:68-75. (Pubitemid 46199221)
168. Halonen J, Halonen P, Järvinen O, Taskinen P, Auvinen T, Tarkka M et al. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. JAMA 2007;297:1562-7. (Pubitemid 46588369)
169. Ho KM, Tan JA. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis. Circulation 2009;119:1853-66.
170. Baker WL, White CM, Kluger J, Denowitz A, Konecny CP, Coleman CI. Effect of perioperative corticosteroid use on the incidence of postcardiothoracic surgery atrial fibrillation and length of stay. Heart Rhythm 2007;4:461-8. (Pubitemid 46613781)
171. Chiappini B, El Khoury G. Risk of atrial fibrillation with high-dose corticosteroids. Expert Opin Drug Saf 2006;5:811-4. (Pubitemid 44669495)
172. Jahangiri M, Camm AJ. Do corticosteroids prevent atrial fibrillation after cardiac surgery? Nat Clin Pract Cardiovasc Med 2007;4:592-3. (Pubitemid 350020365)
173. Christiansen CF, Christensen S, Mehnert F, Cummings SR, Chapurlat RD, S'rensen HT. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med 2009;169:1677-83.
174. van der Hooft CS, Heeringa J, Brusselle GG, Hofman A, Witteman JC, Kingma JH et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 2006;166: 1016-20.
175. Huerta C, Lanes SF, García Rodríguez LA. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology 2005;16:360-6. (Pubitemid 40586712)
176. Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 2005;105:315-8. (Pubitemid 41605083)
177. Aksnes TA, Schmieder RE, Kjeldsen SE, Ghani S, Hua TA, Julius S. Impact of newonset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). Am J Cardiol 2008;101:634-8. (Pubitemid 351625088)
178. Kato T, Yamashita T, Sekiguchi A, Tsuneda T, Sagara K, Takamura M et al. AGEs- RAGE System mediates atrial structural remodeling in the diabetic rat. J Cardiovasc Electrophysiol 2008;19:415-20. (Pubitemid 351457548)
179. Shimano M, Tsuji Y, Inden Y, Kitamura K, Uchikawa T, Harata S et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm 2008;5:451-9.
180. Takahashi N, Kume O, Teshima Y, Yufu K, Nakagawa M, Hara M et al. Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. Circulation 2010:Abstract 10983.
181. Korantzopoulos P, Kokkoris S, Kountouris E, Protopsaltis I, Siogas K, Melidonis A. Regression of paroxysmal atrial fibrillation associated with thiazolidinedione therapy. Int J Cardiol 2008;125:e51-3. (Pubitemid 351418030)